<VariationArchive RecordType="classified" VariationID="12776" VariationName="NR_030286.1(MIR559):n.278_23134del" VariationType="Deletion" Accession="VCV000012776" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-08-06" DateCreated="2016-08-22" MostRecentSubmission="2022-11-19">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="27815" VariationID="12776">
      <GeneList>
        <Gene Symbol="EPCAM" FullName="epithelial cell adhesion molecule" GeneID="4072" HGNC_ID="HGNC:11529" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>2p21</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="47369311" stop="47387020" display_start="47369311" display_stop="47387020" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="47596286" stop="47614166" display_start="47596286" display_stop="47614166" Strand="+" />
          </Location>
          <OMIM>185535</OMIM>
        </Gene>
      </GeneList>
      <Name>NR_030286.1(MIR559):n.278_23134del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2p21</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" outerStart="47377952" innerStart="47378002" innerStop="47400808" outerStop="47400851" display_start="47377952" display_stop="47400851" variantLength="22807" Strand="+" />
      </Location>
      <OtherNameList>
        <Name>22.8-KB DEL</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.(47377952_47378002)_(47400808_47400851)del" Assembly="GRCh38">
            <Expression>NC_000002.12:g.(47377952_47378002)_(47400808_47400851)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="nssv1414998" DB="dbVar" />
        <XRef ID="nsv513770" DB="dbVar" />
        <XRef Type="Allelic variant" ID="185535.0006" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff reviewed the sequence information reported in PubMed 19098912 Supplementary Fig. 3 to determine the location of this allele on the current reference sequence.</Comment>
      <Comment DataSource="NCBI curation" Type="public">22.8-kb deletion beginning in intron 5 of gene EPCAM and ending in the intergenic region upstream of MSH2.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NR_030286.1(MIR559):n.278_23134del AND Lynch syndrome 8" Accession="RCV000013614" Version="27">
        <ClassifiedConditionList TraitSetID="3473">
          <ClassifiedCondition DB="MedGen" ID="C2750471">Lynch syndrome 8</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2009-01-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2009-01-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2016-08-22" MostRecentSubmission="2022-11-19">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16951683</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19098912</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3473" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6886" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Colorectal cancer, hereditary nonpolyposis, type 8</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Lynch syndrome 8</ElementValue>
                <XRef ID="MONDO:0013196" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">LYNCH8</ElementValue>
                <XRef Type="MIM" ID="613244" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.</Attribute>
                <XRef ID="NBK1211" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301390</ID>
                <ID Source="BookShelf">NBK1211</ID>
              </Citation>
              <Citation Type="general" Abbrev="EHTG/ESCP, 2021">
                <ID Source="PubMed">34043773</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Lynch-Syndrome.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, MLH1, MSH2, MSH6, PMS2, EPCAM Pathogenic Variants, Lynch Syndrome (Hereditary Non-polyposis Colon Cancer [HNPCC]), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2021">
                <URL>https://www.nice.org.uk/guidance/ng151</URL>
                <CitationText>UK NICE Guideline NG151, Colorectal cancer, 2021</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2020">
                <URL>https://www.nice.org.uk/guidance/dg42</URL>
                <CitationText>UK NICE Diagnostics Guidance DG42, Testing strategies for Lynch syndrome in people with endometrial cancer, 2020</CitationText>
              </Citation>
              <XRef ID="144" DB="Orphanet" />
              <XRef ID="C2750471" DB="MedGen" />
              <XRef ID="MONDO:0013196" DB="MONDO" />
              <XRef Type="MIM" ID="613244" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="33861" SubmissionDate="2016-08-04" DateLastUpdated="2022-11-19" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="185535.0006_LYNCH SYNDROME 8" title="EPCAM, 22.8-KB DEL_LYNCH SYNDROME 8" />
        <ClinVarAccession Accession="SCV000033861" DateUpdated="2022-11-19" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2009-01-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Chan et al. (2006) reported a family with inheritance, in 3 successive generations, of germline allele-specific and mosaic hypermethylation of the MSH2 gene (609309), without evidence of DNA mismatch repair gene mutation. Three sibs carrying the germline methylation developed early-onset colorectal or endometrial cancers (LYNCH8; 613244), all with microsatellite instability and MSH2 protein loss. The authors demonstrated different methylation levels in different somatic tissues, with the highest level recorded in rectal mucosa and colon cancer tissue, and the lowest in blood leukocytes. Although the underlying mechanism remained unclear, it was considered possible that the methylation is controlled by a genetic event associated with the disease haplotype.</Attribute>
              <Citation>
                <ID Source="PubMed">16951683</ID>
              </Citation>
              <XRef DB="OMIM" ID="609309" Type="MIM" />
              <XRef DB="OMIM" ID="613244" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Ligtenberg et al. (2009) analyzed the family reported by Chan et al. (2006) with heritable MSH2 promoter methylation and identified a heterozygous deletion of 22.8 kb (TACSTD1 cDNA, 555+894_*14194del) that segregated with the disease. The deletion extended from intron 5 of the TACSTD1 gene to approximately 2.4 kb upstream of MSH2, encompassing the 3-prime end of TACSTD1 and leaving the MSH2 promoter intact. Ligtenberg et al. (2009) identified the same mutation in another Chinese family; there was no evidence for a founder mutation. RT- and methylation-specific PCR of tissue samples from affected individuals showed that methylation of MSH2 was limited to TACSTD1-expressing cells.</Attribute>
              <Citation>
                <ID Source="PubMed">19098912</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">16951683</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="EPCAM" />
          </GeneList>
          <Name>EPCAM, 22.8-KB DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">22.8-KB DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="185535.0006" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">LYNCH SYNDROME 8</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="33861" TraitType="Disease" MappingType="Name" MappingValue="LYNCH SYNDROME 8" MappingRef="Preferred">
        <MedGen CUI="C2750471" Name="Lynch syndrome 8" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

